# DT-7012

Source: https://onco.cc/drugs/dt-7012/  
OnCo record `dt-7012` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DT-7012 is an experimental monoclonal antibody from Domain Therapeutics, in phase 2 trials for advanced solid tumours, cutaneous T-cell lymphoma and soft tissue sarcoma.

## Summary

DT-7012 is a monoclonal antibody (depleting) from Domain Therapeutics. An anti-CCR8 antibody designed to remove highly immunosuppressive regulatory T cells from tumours through ADCC and ADCP. Its furthest stage is phase 2, for advanced solid tumours, cutaneous T-cell lymphoma and soft tissue sarcoma (undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma). ClinicalTrials.gov registers it in 3 studies linked below. Phase 1/2 DOMISOL (NCT06819735) recruiting; investigator trials in CTCL (NCT07213882, APHP) and soft tissue sarcoma (NCT07802652, Gustave Roussy, phase 2) not yet recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DT-7012
- Modality: Monoclonal antibody (depleting)
- Mechanism: An anti-CCR8 antibody designed to remove highly immunosuppressive regulatory T cells from tumours through ADCC and ADCP.

## Sources

- Domain Therapeutics: kainovatx.com: https://www.kainovatx.com/
- Domain Therapeutics: kainovatx.com: https://www.kainovatx.com/
- ClinicalTrials.gov: trials of DT-7012: https://clinicaltrials.gov/search?intr=DT-7012

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [Kainova Therapeutics](https://onco.cc/companies/domain-therapeutics/)
- trials: [A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)](https://onco.cc/trials/nct07213882/), [Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma](https://onco.cc/trials/nct07802652/), [Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06819735/)

---
JSON: https://onco.cc/api/v1/entities/dt-7012.json